BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique COMMUNIQUÉ DE PRESSE BIOPHTA lève 6,5 millions d'euros en amorçage pour emmener son nouveau standard de traitement oculaire en clinique Ce tour de table a été réalisé par UI Investissement (via le...

BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage PRESS RELEASE BIOPHTA raises 6.5 million Euros Seed Funding to transition its New Standard of Care for Eye Diseases to the Clinical stage The seed round was co-led by UI Investissement (via the...

Théa Open Innovation and Galimedix announce strategic partnership to develop and commercialize GAL-101, a Phase 2/3-ready small molecule, to treat ophthalmic indications with high unmet medical need Galimedix eligible for upfront payment plus various success-based milestone payments and royalties on future net salesEquity investment by Théa Open Innovation into Galimedix supports further...